Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: New York
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Puma Biotechnology Inc

+ Add to Watchlist


217.9400 USD 8.1900 3.62%

As of 20:04:03 ET on 01/28/2015.

Snapshot for Puma Biotechnology Inc (PBYI)

Open: 229.6800 Day's Range: 214.0300 - 229.9900 Volume: 531,155
Previous Close: 226.1300 52wk Range: 53.6300 - 279.3700 1-Yr Rtn: +74.09%

Stock Chart for PBYI

No chart data available.
  • PBYI:US 217.9400
  • 1D
  • 1M
  • 1Y
Interactive PBYI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PBYI

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -3.7100
Est. EPS (USD) (12/2014) -3.5120
Est. PEG Ratio -
Market Cap (M USD) 6,847.20
Shares Outstanding (M) 31.42
30 Day Average Volume 295,366
Price/Book (mrq) 46.3541
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/03/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PBYI

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for PBYI

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company. The Company develops novel therapeutics for the treatment of various forms of cancer. Puma focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.

Alan H AuerbachChairman/President/CEO/FounderRichard P BryceSenior VP:Clinical Rsch & Dev
Charles R EylerSenior VP:Finance & AdministrationRichard B PhillipsSenior VP:Regulatory Affairs
More Company Profile & Key Executives for PBYI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil